Skip to main content

Advertisement

Table 3 Diagnostic performance of preoperative CE-MRI in different histologic and biologic tumor subtypes

From: Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Percentage (95% CI) Ductal Lobular Others P value* HR+ HR- P value*
pCR rate: 33% 12% 10% 18% 40%
Sensitivity 76%
(64–86%)
0%
(0–76%)
100%
(11–100%)
0.120 77%
(55–92%)
73%
(59–85%)
0.777
Specificity 70%
(62–78%)
67%
(35–85%)
58%
(32–77%)
0.488 65%
(55–76%)
69%
(57–79%)
0.631
PPV 56%
(45–66%)
0%
(0–47%)
20%
(2–51%)
0.003 33%
(20–47%)
61%
(47–73%)
0.004
NPV 85%
(77–91%)
83%
(46–95%)
100%
(65–100%)
0.536 93%
(84–97%)
80%
(68–89%)
0.040
Accuracy 72%
(65–78%)
59%
(33–81%)
62%
(37–81%)
0.024 67%
(58–75%)
71%
(62–78%)
0.004
  1. CE-MRI contrast-enhanced magnetic resonance imaging, pCR pathologic complete response, PPV positive predictive value, NPV negative predictive value
  2. *Fisher’s exact test for all subgroups